Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioactivated Glucoraphanin in Neurodegenerative Diseases
NCT07360977Active, not recruiting
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of glucoraphanin in Parkinson's disease (PD), multiple sclerosis (MS), Neuromuscular Diseases (NMDs) and 1 more (6 arms), sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Primary endpoints: Unified Parkinson's Disease Rating Scale Total Score at 12 months, Hoehn and Yahr scale at 12 months and 16 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
glucoraphanin
03
Conditions
Parkinson's disease (PD)multiple sclerosis (MS)Neuromuscular Diseases (NMDs)degenerative diseases
Beyond the preview
Go deeper on NCT07360977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360977.